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Abstract
Background: The American College of Surgeons National Surgical Quality Improvement Program (ACS-
NSQIP) was started in 2004. Presently, 58% of the 198 hospitals participating in ACS-NSQIP are
academic or teaching hospitals. In 2008, ACS-NSQIP initiated a number of changes and made risk-
adjusted data available for use by participating hospitals. This analysis explores the ACS-NSQIP data-
base for utility in developing hepato-pancreato-biliary (HPB) surgery-specific outcomes (HPB-NSQIP).
Methods: The ACS-NSQIP Participant Use File was queried for patient demographics and outcomes for
49 HPB operations from 1 January 2005 through 31 December 2007. The procedures included six
hepatic, 16 pancreatic and 23 complex biliary operations. Four laparoscopic or open cholecystectomy
operations were also studied. Risk-adjusted probabilities for morbidity and mortality were compared with
observed rates for each operation.
Results: During this 36-month period, data were accumulated on 9723 patients who underwent major
HPB surgery, as well as on 44 189 who received cholecystectomies. The major HPB operations included
2847 hepatic (29%), 5074 pancreatic (52%) and 1802 complex biliary (19%) procedures. Patients
undergoing hepatic resections were more likely to have metastatic disease (42%) and recent chemo-
therapy (7%), whereas those undergoing complex biliary procedures were more likely to have significant
weight loss (20%), diabetes (13%) and ascites (5%). Morbidity was high for hepatic, pancreatic and
complex biliary operations (20.1%, 32.4% and 21.2%, respectively), whereas mortality was low (2.3%,
2.7% and 2.7%, respectively). Compared with laparoscopic cholecystectomy, the open operation was
associated with higher rates of morbidity (19.2% vs. 6.0%) and mortality (2.5% vs. 0.3%). The ratios
between observed and expected morbidity and mortality rates were <1.0 for hepatic, pancreatic and
biliary operations.
Conclusions: These data suggest that HPB operations performed at ACS-NSQIP hospitals have
acceptable outcomes. However, the creation of an HPB-NSQIP has the potential to improve quality,
provide risk-adjusted registries with HPB-specific data and facilitate multi-institutional clinical trials.
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Introduction
The concept of a National Surgical Quality Improvement
Program (NSQIP) originated in the Department of Veterans
Affairs (VA).1 In response to a law passed by the United States
Congress, a National VA Surgical Risk Study (NVASRS) was
planned in 1991. The NVASRS prospectively collected data on
major operations at 44 VA hospitals and developed risk-adjusted
models for 30-day morbidity and mortality for eight surgical spe-
cialties.2,3 Using this experience, the VA-NSQIP was established in
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1994 at all 132 VA medical centres. Over the next few years,
VA-NSQIP was able to demonstrate a 45% reduction in morbid-
ity, a 27% decrease in mortality and major cost savings.4
In 1999 surgeons at three university hospitals joined the VA
programme as an alpha test of NSQIP in the private sector. Again,
NSQIP was demonstrated to reduce morbidity, mortality and cost
at university hospitals.5 This success led to the Patient Safety in
Surgery (PSS) Study submitted by the American College of Sur-
geons and funded from 2001 to 2004.6 The PSS was conducted in
128 VA medical centres as well as in 14 university beta sites and
covered major general and vascular surgery. Data were collected
on over 145 000 general and 39 000 vascular operations. Thirty-
day unadjusted mortality for men was significantly lower in the
private sector (2.03% vs. 2.62%; P < 0.001).7
In 2004 the American College of Surgeons (ACS) initiated ACS-
NSQIP. By December 2008, 198 hospitals were receiving ACS-
NSQIP feedback on their surgical outcomes and reliable data on
over 350 000 operations had been accumulated. However, 58%
of the participating hospitals were larger academic or teaching
centres and only a small percentage of smaller community hospi-
tals were involved. In addition, the majority of the data repre-
sented a random sample of all general and vascular operations.
Therefore, in an effort to improve ACS-NSQIP, a number of
modifications were recommended.8 These recommendations
include: (i) establishing multiple specialty-specific modules; (ii)
100% sampling of selected procedures; (iii) establishing a limited
set of generic and more procedure-specific patient characteristics;
(iv) setting a focus on procedure-specific outcomes; (v) the addi-
tion of processes of care measures; (vi) the reporting of
procedure- and surgeon-specific outcomes, and (vii) the incorpo-
ration of hierarchical modelling techniques for lower-volume pro-
grammes. In 2008 ACS-NSQIP established a Participant Use File,
which houses data on all patients in the programme from 2005 to
2007. The aim of this analysis was to explore the ACS-NSQIP
database for utility in developing hepato-pancreato-biliary (HPB)
surgery-specific outcomes (HPB-NSQIP).
Materials and methods
American College of Surgeons National Surgical
Quality Improvement Program
Over the first 4 years of its existence, the ACS-NSQIP has grown
significantly. By December 2008, 198 hospitals were entering data
and receiving risk-adjusted outcomes (Fig. 1A). The majority of
these hospitals were large; 49% of them had more than 500
licensed beds and 33% had 300–499 beds. ACS-NSQIP employs a
systematic sampling process which uses an 8-day cycle whereby
the first 40 cases to fulfil inclusion and exclusion criteria at each
participating hospital are randomly selected. The vast majority of
major operations are acceptable for inclusion in ACS-NSQIP
every 8 days. Exclusions include: (i) minor cases; (ii) cases with
subjects aged under 16 years; (iii) more than five inguinal hernias
or breast lumpectomies per 8-day cycle; (iv) trauma and trans-
plant operations, and (v) American Society of Anesthesiology
(ASA) class 6 cases. ACS-NSQIP presently includes general and
vascular surgery or, for lower-volume hospitals, a multispecialty
option (cardiac, gynaecological, neurological, orthopaedic, oto-
laryngological, plastic, thoracic and urological surgery). Out-
comes are assessed at 30 days after the index operation and highly
standardized and validated data definitions are employed.
Surgical clinical nurse reviewers (SCNRs) are trained and cer-
tified, and receive continuing education as well as ongoing
support. For each patient or operation, 136 variables are collected.
Preoperative data include six demographic, 44 clinical and 13
laboratory variables. Intraoperative data include 11 operative, 16
clinical and three complication variables. Postoperative 30-day
outcomes include 20 complications as well as 12 laboratory and 10
discharge variables. Real-time benchmarking allows outcomes to
be compared with those of other ACS-NSQIP hospitals using
online reports. Semi-annual reports provide risk-adjusted com-
parisons of all ACS-NSQIP hospitals for multiple morbidity out-
comes, as well as for mortality outcomes. In 2008 a Participant Use
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Figure 1 (A) Number of hospitals participating in the American
College of Surgeons National Surgical Quality Improvement Program
(ACS-NSQIP). (B) Number of procedures recorded in the ACS-
NSQIP Participant Use File
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File (PUF) containing all cases entered during 2005–2007 became
available (Fig. 1B). In 2007 data on more than 200 000 operations
were entered into the PUF.
Participant Use File
To assure the high quality of the data, ACS-NSQIP conducts inter-
rater reliability audits of the SCNRs, requires six web-based train-
ing modules, and provides an online decision support system. The
overall disagreement rate for all 136 variables is only 2.5%. In
addition to the case inclusion and exclusion criteria described
above, hospital inclusion and exclusion criteria are imposed for
the PUF. Only cases included in the morbidity and mortality
observed/expected (O/E) ratio analyses are included in the PUF. A
site may be excluded from the O/E calculation and the PUF if: (i)
the 30-day follow-up rate is < 80%; (ii) the inter-rater reliability
audit score is >5%, or (iii) fewer than 200 cases have been sub-
mitted in the calendar year. Nevertheless, the PUF has a number of
deliberate limitations that aim to ensure patient privacy, as well as
limitations imposed by resource constraints. These limitations
pertain to: (i) the generic nature of most outcome measures; (ii)
the exclusion of patients under 17 years of age and the lumping
together of those aged over 90 years; (iii) the fact that follow-up is
limited to 30 days; (iv) the removal of absolute dates; (v) the
de-identification of participating sites; (vi) the absence of records
of many preventative measures; (vii) the relatively small number
of participating hospitals; (viii) incomplete sets of some preop-
erative laboratory data, and (ix) limited information on patho-
logical diagnosis and cancer therapies.
Morbidity and mortality indices
Morbidity and mortality rates are calculated by sorting PUF data
according to the principal operative procedure, which is defined as
the most complex of all the procedures performed by the operat-
ing team. For example, if a hepatectomy and a cholangiojejunos-
tomy are performed for a perihilar cholangiocarcinoma, the
procedure is included with major hepatectomies and not with
complex biliary operations. Procedures are listed according to
current procedure terminology (CPT) codes, which are employed
nationally in the USA for billing purposes. Outcomes for 49 HPB
operations carried out between 1 January 2005 and 31 December
2007 were assessed. The procedures included six hepatic, 16 pan-
creatic and 23 complex biliary operations. Four laparoscopic or
open cholecystectomy operations were also studied. Data were
available on 9723 HPB operations and 44 189 cholecystectomies
(Table 1). Of the HPB operations, 29% were hepatic, 52% were
pancreatic and 19% were complex biliary procedures (Fig. 2). For
each patient or procedure recorded in the PUF, 239 variables are
listed, including the probability of morbidity and the probability
of mortality. The probabilities of morbidity and mortality are
based on a logistic regression analysis which uses the patient’s
preoperative characteristics as the independent or predictive vari-
ables. For example, patients with lower serum albumin, poorer
functional states and more co-morbidities, who are undergoing
larger operations, will have a higher expected morbidity and mor-
tality than more functional patients undergoing smaller opera-
tions. These probability analyses are performed independently on
data from each calendar year. The observed (O) morbidity or
mortality was divided by the expected (E, probability) morbidity
or mortality to obtain the morbidity and mortality observed/
expected (O/E) indices.
Results
Hepatic morbidity and mortality
Data for six hepatic surgery procedures are presented in Table 2.
Patients undergoing hepatectomy were more likely to have meta-
static disease (42%) and recent chemotherapy (7%) than those
undergoing pancreatectomy or complex biliary operations. Minor
(partial lobe) hepatectomies accounted for 55% of the 2843
operations. Morbidity (35.7%) and mortality (5.2%) were highest
for extensive hepatectomies (n = 230). Right hepatectomies were
associated with higher morbidity (27.9% vs. 21.5%) and mortality
(3.7% vs. 0.9%) than left hepatectomies. Laparoscopic hepatec-
tomy was performed in 350 patients (13%) with low morbidity
(4.6%) and mortality (0.8%). Interestingly, the expected
Table 1 American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Participant Use File data for 2005–
2007 for hepato-pancreato-biliary (HPB) and cholecystectomy cases
Hepatic Pancreatic Biliary* HPB Cholecystectomy
Procedures 6 16 23 45 4
Number 2847 5074 1802 9723 44 189
*Complex procedures
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Figure 2 Number and percentage of hepato-pancreato-biliary (HPB)
procedures in the ACS-NSQIP Participant Use File
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morbidity for laparoscopic hepatectomy was less than 20% of that
for open minor hepatectomies and less than 12% of the morbidity
for major hepatectomies. Similarly, the expected mortality for
laparoscopic hepatectomy was only a fraction of that for open
hepatectomy, which suggests that patients who underwent laparo-
scopic procedures were much healthier. For all hepatic surgery, the
observed morbidity (Fig. 3) and mortality (Fig. 4) were less than
expected, yielding a morbidity index of 0.67 and a mortality index
of 0.92.
Pancreatic morbidity and mortality
Data for eight pancreatectomies and eight other pancreatic
surgery procedures are presented in Table 3. Of 1391 distal pan-
createctomies, 89% were performed without a pancreatojejunos-
tomy or a subtotal resection. For distal pancreatectomy, morbidity
(26.8%) and mortality (1.9%) were higher than expected (O/E
indices of 1.58 and 1.36, respectively). Of the 2889 proximal
pancreatectomies, 58% were performed with a gastrectomy
(Whipple) and 42% with pylorus preservation (pylorus preserv-
ing pancreatoduodenectomy [PPPD]). All but 117 of these opera-
tions (4%) were performed with a pancreatojejunostomy
anastomosis. Morbidity and mortality indices were similar for
Whipple and PPD procedures, but mortality was higher for the
Whipple operations (3.6% vs. 3.0%). Of the 5074 pancreatic
operations, 4373 (86%) were pancreatectomies, and all other
operations were uncommon. The observed morbidity for pancre-
atectomy (32.4%) was higher than for the other pancreatic opera-
tions (22.5%). However, the morbidity index for pancreatectomy
was lower (0.94 vs. 1.40). Both the observed and expected mor-
bidity for pancreatic surgery were higher than for hepatic or
complex biliary surgery (Fig. 3). The observed mortality for pan-
createctomy (2.7%) was higher than for other pancreatic surgery
(0.9%), as was the mortality index (1.01 vs. 0.57) (Table 3). The
observed and expected mortality for pancreatectomy were slightly
higher than for hepatectomy (Fig. 4).
Complex biliary morbidity and mortality
Data for nine complex biliary procedures are presented in Table 4.
These 1537 operations accounted for 85% of the complex biliary
procedures. These patients were more likely to have significant
weight loss (20%), diabetes (13%) and ascites (5%) than patients
undergoing hepatectomy or pancreatectomy. Numbers of these
Table 2 Hepatic surgery morbidity, mortality and observed/expected indices
CPT code Principal procedure n Observed
morbidity, %
Expected
morbidity, %
Morbidity
index
Observed
mortality, %
Expected
mortality, %
Mortality
index
47120 Hepatectomy, partial lobe 1357 18.1 26.4 0.69 1.8 2.2 0.82
47122 Hepatectomy, extensive 230 35.7 49.8 0.72 5.2 3.7 1.41
47125 Hepatectomy, left 233 21.5 42.0 0.51 0.9 3.1 0.29
47130 Hepatectomy, right 512 27.9 46.2 0.60 3.7 3.4 1.09
47379 Hepatectomy, laparoscopic 350 4.6 5.7 0.81 1.1 0.8 1.38
47380 Ablation, radiofrequency 165 21.8 18.8 1.16 2.4 2.7 0.89
Total 2847 20.1 30.1 0.67 2.3 2.5 0.92
CPT code, current procedure terminology
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nine operations varied from 422 to 33, whereas the other 14
complex biliary procedures accounted for 265 operations, a mean
of 18.9 cases per procedure. Hepatico- or cholangiojejunostomy
accounted for 766 of the complex biliary operations (43%). The
observed morbidity was 32% for these operations, which was
modestly less than expected. The mortality for these biliary-
enteric anastomoses was 2.7%, which, again, was moderately less
than expected. Only 435 open common duct explorations (CDEs)
were carried out, most (n = 299) of which were performed without
a drainage procedure. Interestingly, 273 laparoscopic CDEs were
performed. Therefore, 37% of the CDEs were accomplished lap-
aroscopically. The morbidity for open CDE was 22%, compared
Table 3 Pancreatic surgery morbidity, mortality and observed/expected indices
CPT code Principal procedure n Observed
morbidity, %
Expected
morbidity, %
Morbidity
index
Observed
mortality, %
Expected
mortality, %
Mortality
index
Pancreatectomy
48140 Pancreatectomy, distal w/o PJ 1241 26.8 17.0 1.58 1.9 1.4 1.36
48145 Pancreatectomy, distal w PJ 103 35.0 18.0 1.94 1.9 1.0 1.90
48146 Pancreatectomy, distal subtotal 47 31.9 25.2 1.27 4.3 2.4 1.79
48150 Pancreatectomy, proximal Whipple w PJ 1588 37.0 44.2 0.84 3.3 3.5 0.94
48152 Pancreatectomy, proximal Whipple w/o PJ 70 48.6 42.0 1.16 10.0 4.7 2.13
48153 Pancreatectomy, proximal PPPD w PJ 1184 30.8 42.2 0.73 2.1 2.9 0.72
48154 Pancreatectomy, proximal PPPD w/o PJ 47 36.2 40.9 0.89 8.5 5.3 1.60
48155 Pancreatectomy, total 93 37.6 25.0 1.50 5.4 3.4 1.59
Total 4373 32.4 34.6 0.94 2.7 2.7 1.01
Other pancreatic
48120 Excision of lesion 113 18.6 11.8 1.58 0.0 0.6 0.00
48148 Excision of ampulla 20 30.0 15.5 1.94 0.0 1.1 0.00
48180 Pancreatojejunostomy, side-to-side* 63 23.8 18.3 1.30 1.6 0.8 2.00
48510 Pseudocyst, external drainage 52 32.7 31.3 1.04 1.9 7.1 0.27
48520 Pseudocyst, cystenterostomy 131 26.7 21.4 1.25 1.5 2.2 0.68
48540 Pseudocyst, Roux-Y 96 16.7 16.3 1.02 0.0 0.9 0.00
48548 Pancreatojejunostomy, side-to-side 70 22.9 19.4 1.18 0.0 0.9 0.00
48999 Unlisted 156 20.5 7.5 2.70 1.3 0.7 1.86
Total 701 22.5 16.1 1.40 0.9 1.5 0.57
*Code deleted in 2007
CPT code, current procedure terminology; PJ, pancreatojejunostomy; PPPD, pylorus preserving pancreatoduodenectomy
Table 4 Complex biliary surgery morbidity, mortality and observed/expected indices
CPT code Principal procedure n Observed
morbidity, %
Expected
morbidity, %
Morbidity
index
Observed
mortality, %
Expected
mortality, %
Mortality
index
47420 Choledochotomy, CDE,
sphincteroplasty
61 27.9 23.7 1.18 4.9 4.0 1.22
47460 Transduodenal sphincteroplasty 63 12.7 11.9 1.07 0.0 0.6 0.00
47564 Lap chole w CDE 273 3.3 9.1 0.36 0.4 1.1 0.36
47610 Open chole w CDE 299 22.1 22.9 0.97 5.7 5.0 1.14
47612 Open chole w CDE w CD ent 75 14.7 20.5 0.72 0.0 3.4 0.00
47760 Hepaticojejunostomy 125 20.0 27.2 0.74 1.6 2.7 0.59
47765 Cholangiojejunostomy 33 33.3 39.1 0.85 3.0 2.9 1.03
47780 Roux-Y hepaticojejunostomy 422 29.9 31.2 0.96 2.8 3.7 0.76
47785 Roux-Y cholangiojejunostomy 186 28.5 38.3 0.74 3.2 3.4 0.94
Total 1537* 21.2 24.0 0.88 2.7 3.2 0.85
*14 other procedure codes accounted for 265 operations (mean = 18.9 procedures per operation type)
CPT code, current procedure terminology; CDE, common duct exploration; Lap chole, laparoscopic cholecystectomy; CD ent, choledochoenteric
anastomosis
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with only 3.3% for laparoscopic CDE. However, the expected
morbidity for open CDE was 23%, compared with 9% for laparo-
scopic CDE, which again suggests that patients who underwent
the operation laparoscopically were healthier. The overall morbid-
ity and mortality indices for these 14 complex biliary operations
(Table 4) were 0.88 and 0.85, respectively. The observed morbidity
for complex biliary operations was similar to that for hepatec-
tomy, but lower than that for pancreatectomy (Fig. 3). Interest-
ingly, the observed mortality for the complex biliary operations
(2.7%) was equal to that for pancreatectomy and exceeded that for
hepatectomy (2.3%) (Fig. 4). Moreover, the expected mortality
(3.2%) was highest for complex biliary surgery (Fig. 4). Thus, the
morbidity O/E index was lowest for hepatectomy, whereas the
mortality O/E index was lowest for complex biliary surgery
(Fig. 5).
Cholecystectomy morbidity and mortality
Data for four cholecystectomy procedures are presented in
Table 5. The 44 189 cholecystectomies in the PUF database out-
numbered the HPB operations by more than 4.5 to one. Of the
44 189 cholecystectomies, 40 188 (92%) were performed laparo-
scopically. An operative cholangiogram was accomplished in only
27% of the laparoscopic and 19% of the open cholecystectomies.
The observed morbidity for laparoscopic cholecystectomy (6.0%)
was much lower than for open cholecystectomy (19.2%). Simi-
larly, the observed mortality for laparoscopic cholecystectomy
(0.3%) was much lower than for open cholecystectomy (2.5%).
However, the expected morbidity of laparoscopic cholecystectomy
was approximately one-third of that for the open procedure. Simi-
larly, the expected mortality of laparoscopic cholecystectomy was
less than 20% of that for open cholecystectomy. Similar to the data
for laparoscopic hepatectomy and laparoscopic CDE, these chole-
cystectomy outcomes suggest that patients who underwent this
operation were healthier than those who required an open
operation. Thus, the morbidity and mortality O/E indices for
laparoscopic cholecystectomy are lower than those for open chole-
cystectomy, but all of these ratios are < 1.0 (Fig. 6).
Discussion
The American College of Surgeons National Surgical Quality
Improvement Program has grown rapidly since its inception in
2004. During 2005–2007, data on nearly 10 000 major HPB opera-
tions and more than 44 000 cholecystectomies were made avail-
able in the PUF. Among the major HPB operations, 29% were
hepatic, 52% pancreatic and 19% complex biliary procedures.
Morbidity was highest for pancreatectomy (32.4%) compared
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Figure 5 Hepato-pancreato-biliary morbidity and mortality
observed/expected indices. Hep, hepatic procedure; Panc, pancre-
atic procedure; Bil, biliary procedure
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Figure 6 Cholecystectomy morbidity and mortality observed/
expected indices. Lap, laparoscopic
Table 5 Cholecystectomy morbidity, mortality and observed/expected indices
CPT code Principal procedure n Observed
morbidity, %
Expected
morbidity, %
Morbidity
index
Observed
mortality, %
Expected
mortality, %
Mortality
index
47562 Laparoscopic chole 29 245 3.2 5.7 0.56 0.3 0.5 0.60
47563 Lap chole w cholangio 10 943 3.4 6.8 0.50 0.3 0.7 0.43
47600 Open cholecystectomy 3 237 18.6 19.4 0.96 2.4 3.5 0.69
47605 Open chole w cholangio 764 16.5 18.3 0.90 2.7 3.1 0.87
Total 44 189 4.6 7.2 0.64 0.5 0.8 0.63
CPT code, current procedure terminology; chole, cholecystectomy; Lap, laparoscopic; cholangio, cholangiogram
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with complex biliary operations (21.2%) or hepatectomy (20.1%).
Mortality was higher for pancreatectomy (2.7%) and complex
biliary surgery (2.7%) than for hepatectomy (2.3%). Morbidity
and mortality were much lower for laparoscopic hepatectomy,
CDE and cholecystectomy than for comparable open operations.
However, the expected morbidity and mortality in patients who
underwent these operations laparoscopically were also much
lower, indicating a healthier patient population. The O/E morbid-
ity and mortality indices for both major HPB operations and
cholecystectomy were all < 1.0. This analysis suggests that ACS-
NSQIP hospitals are performing HPB surgery safely.
The success of ACS-NSQIP can be attributed to several core
strengths.8 These attributes include: (i) data abstraction by
trained nurses; (ii) rigorously defined variables; (iii) a compre-
hensive set of clinical and laboratory risk factors; (iv) well-
validated risk adjustment models, and (v) external auditing of
data for completeness and accuracy. As a result, participating
hospitals receive very robust risk-adjusted estimates of their sur-
gical morbidity and mortality. By contrast, hospital enrolment
has been limited by several problems. These issues include: (i)
high costs; (ii) the relatively ‘generic’ nature of most perfor-
mance measures; (iii) the lack of procedure-specific outcomes;
(iv) the paucity of processes of care measures, and (v) the
absence of surgeon-specific data. In response to these concerns,
a new leadership and organizational structure was created for
ACS-NSQIP in 2007.8 The Measurement and Evaluation Com-
mittee was charged with developing a blueprint for a new and
improved ACS-NSQIP. A key recommendation has been to
develop a specialty-specific approach which evolves away from
the random sampling of all procedures towards 100% sampling
of selected procedures.
A new version of ACS-NSQIP being developed in 2009 will
include five ‘core’ and seven ‘optional’ procedures (Table 6). Two
of the five core procedures, cholecystectomy for acute cholecystitis
and pancreatectomy, are HPB operations. Similarly, two of the
seven optional procedures, cholecystectomy (all) and hepatec-
tomy, are HPB operations. These procedures were chosen because
of their contributions to the overall number of major adverse
events. Thus, only the relatively uncommon other HPB operations
(Table 3) and complex biliary procedures (Table 4) will not be
included in the next version of ACS-NSQIP. In addition, data on
12–15 patient- and procedure-specific variables, such as cirrhosis,
preoperative biliary drainage, vascular resection, liver failure and
pancreatic fistula, will be gathered with the next version of ACS-
NSQIP. Therefore, extension to a full HPB-NSQIP as a specialty-
specific module should be straightforward. Efforts are currently
underway to reduce the number of ‘generic’ patient characteristics
and risk factors as previous studies based on NSQIP data suggest
that risk modules require fewer than 10 variables.2,3,8,9 A reduction
of the number of core covariates to focus on those that will dis-
criminate hospital- or surgeon-level variations in outcomes will
reduce the burden and cost of data collection. The adoption of a
minimum set of core covariates will also allow for the inclusion
of important risk factors for specific procedures, as well as
procedure-specific outcomes.
The types of data that might be included as an HPB-NSQIP
option is developed are outlined in Table 7. A basic demographic
variable might be the definition of an ‘HPB surgeon’. Key preop-
erative risk factors to be added in HPB-NSQIP would include: (i)
hepatobiliary variables such as cirrhosis and biliary obstruction;
(ii) diagnostic tests; (iii) local conditions, such as cholecystitis or
pancreatitis; (iv) antecedent related procedures, such as endo-
Table 6 New American College of Surgeons National Surgical
Quality Improvement Program core and optional general surgery
procedures
Core procedures Optional procedures
Cholecystectomy (acute
cholecystitis)
Cholecystectomy (all)
Colectomy Proctectomy (rectal cancer)
Gastric bypass Oesophagectomy
Pancreatectomy Hepatectomy
Ventral herniorrhaphy Appendectomy
Small bowel obstruction surgery
Thyroidectomy
Table 7 Potential Hepato-Pancreato-Biliary National Surgical Quality
Improvement Program (HPB-NSQIP) specific data
Preoperative risk factors
Hepatobiliary – cirrhosis, biliary obstruction
Methods of diagnosis
Concurrent local conditions
Antecedent related procedures
Related prior surgery
Neoadjuvant therapy
Operative information
Procedure-specific
Hepatic – number of segments, Pringle, drains
Pancreatic – vascular resection, reconstruction, drains
Biliary – cholangiography, conversion, drains
Organ-specific
Hepatic – fibrosis, fat
Pancreatic – texture, duct
Biliary – cholecystitis, cholangitis
Outcome information
Procedure-specific
Hepatic – liver failure, biloma
Pancreatic – fistula, delayed gastric emptying
Biliary – bile duct injury, cholangitis
Postoperative interventions
Pathology (ICD-9-CM)
Malignant – type, location, resection status
Tumour–nodes–metastases (TNM)
Benign – type, size, location
Adjuvant therapy
Survival
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scopic sphincterotomy; (v) related prior surgery, such as cholecys-
tectomy, and (vi) neoadjuvant therapies. In addition to HPB-
specific procedure codes, operative information might include: (i)
data not currently provided by these codes, such as ischaemic
preconditioning, vascular resection and the use of drains, and (ii)
organ specifics such as fibrosis, steatosis and inflammation. More-
over, outcome information to be added in HPB-NSQIP would
include additional: (i) procedure-specific morbidities; (ii) postop-
erative interventions; (iii) pathological data; (iv) adjuvant chemo-,
radio- or immune therapy, and (v) for research purposes, patient
survival. Finally, the new ACS-NSQIP and HPB-NSQIP would
include process of care measures such as those presently required
by the Surgical Care Improvement Program (SCIP).
Several prior studies have reported single-institution
outcomes of relatively large numbers of patients undergoing
hepatectomy.10–13 Similarly, the NSQIP Patient Safety in Surgery
(PSS) Study reported the outcomes of 237 liver resections at VA
hospitals compared with 783 similar operations at university
hospitals.14–16 Using similar definitions, the current analysis had
slightly lower morbidity (20.1% vs. 22.6%) and mortality (2.3%
vs. 2.6%) rates than those calculated for university hospital
patients in the PSS Study. In addition, the number of patients in
the current analysis (2847) exceeds those of the prior reports.10–16
The importance of volume in outcomes for pancreatectomy has
been well documented.17–21 VA-NSQIP,21 large series from single
institutions,22 and comparative VA and university data on pancre-
atectomy in the PSS Study23 have been reported. The current
analysis involved 4373 patients compared with 1069 in the PSS
Study, with similar overall morbidity (32.4% vs. 33.8%) and mor-
tality (2.7% vs. 2.5%) to the 692 university patients. Analyses of
hepatico- or cholangiojejunostomy have generally focused on
benign24,25 or malignant26,27 biliary strictures. Thus, the current
data on complex biliary surgery are relatively unique. In the PSS
Study, data on laparoscopic cholecystectomy were available on
7238 men7 and 4460 women.28 However, the current analysis
involves nearly four times as many patients and provides more
robust outcome data.
In the new ACS-NSQIP and the future HPB-NSQIP, surgeon-
specific performance data for both process and outcome measures
would be more feasible. Although small sample size would be an
issue, some data, such as those pertaining to compliance with
antibiotic guidelines, could be aggregated across multiple HPB
procedures. These types of data would be applicable to the Ameri-
can Board of Surgery Maintenance of Certification programme
and would also meet surgeon-credentialing criteria for the Joint
Commission on the Accreditation of Healthcare Organizations.
The adoption of hierarchical modelling techniques rather than
logistic regression would provide better data for low-volume pro-
grammes and would more reliably identify hospital outliers.8
Thus, the creation of an HPB-NSQIP as a further modification of
ACS-NSQIP has the potential to improve quality, provide risk-
adjusted registries with HPB-specific data and facilitate multi-
institutional clinical trials.
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